Contingency Management and Pharmacotherapy for Smoking Cessation

Cigarette Smoking Clinical Trial

— Donaghue  

Official title:

Contingency Management and Pharmacotherapy for Smoking Cessation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00683280
• Other study ID #: 08-035-3
• Secondary ID: DF 07-028
• Status: Completed
• Phase: N/A
• First received: May 14, 2008
• Last updated: January 11, 2018
• Start date: May 2008
• Est. completion date: August 2010

Study information

• Verified date: January 2018
• Source: UConn Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In total, 70 smokers will be randomized to: standard of care smoking cessation medication varenicline alone (an FDA-approved smoking cessation medication) or varenicline plus contingency management (CM) (a behavioral procedure with rewards for target behaviors, like smoking abstinence). Patients in both conditions will receive varenicline for 12 weeks with standard smoking cessation therapy and regular breath and urine sample monitoring for smoking. Patients assigned to CM will earn chances to win prizes for each breath sample that tests negative for smoking, and urine samples that test negative for smoking will result in even greater chances for prizes. More CM patients are expected to achieve and maintain abstinence than patients receiving varenicline alone.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 59
• Est. completion date: August 2010
• Est. primary completion date: August 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• smoke >10 cigarettes/day, with no abstinent period exceeding 3 months in past year

• expired CO of >8 ppm

• self-reported desire to stop smoking

• >18 years of age

• resting systolic BP<160 mmHg and diastolic BP<100 mmHg and otherwise in good health

• if on antihypertensive medication, have not changed medications in the past month and do not intend to change in next 3 months

• English speaking

Exclusion Criteria:

• receipt of smoking cessation treatment (behavioral or pharmacological) in past month

• serious or unstable medical disease in past 6 months, including myocardial infarction, cancer, congestive heart failure, kidney failure, stroke, or seizures

• evidence or history of allergic reactions contraindicating varenicline or clinically significant laboratory or electrocardiographic (ECG) abnormalities

• breastfeeding, pregnant or not using effective contraception if a woman of childbearing potential

• arm circumference of >42 cm

• serious psychiatric illness in past 6 months (e.g., schizophrenia, psychosis, suicide risk, drug or alcohol dependence other than nicotine)

• use of tobacco containing products other than cigarettes in past month and do not agree to abstain from use of these products during study participation

• ongoing use of any of the following medications: nicotine replacement therapies, monoamine oxidase inhibitors, antipsychotics, mood stabilizers, or naltrexone

• in recovery for pathological gambling, due to potential similarity with prize CM, although no increases in gambling have been noted

Related Conditions & MeSH terms

• Cigarette Smoking

Intervention

Behavioral:
• contingency management
Prize-based contingency management, with the opportunity to earn prizes for expired carbon monoxide levels reading 6ppm or less and urinary cotinine levels reading 30ng/ml or less for 4 weeks.

Other:
• Standard of Care
varenicline (smoking cessation medication) 0.5mg po daily Days 1-3, 0.5mg po twice daily Days 4-7, 1.0 mg po twice daily Days 8-84.
• Standard of Care
Twice weekly brief counseling based on public health service guidelines for quitting smoking.

Locations

Country	Name	City	State
United States	University of Connecticut Health Center	Farmington	Connecticut

Sponsors (2)

Lead Sponsor	Collaborator
UConn Health	Donaghue Medical Research Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Smoking abstinence based on expired carbon monoxide tests, urinary cotinine tests and self-report.		weeks 5, 12 & 24
Secondary	Changes from baseline in ambulatory 24-hour systolic blood pressure.		6 and 24 weeks following the initiation of medication